Insider Selling: Atara Biotherapeutics (NASDAQ:ATRA) CEO Sells 1,000 Shares of Stock

Atara Biotherapeutics (NASDAQ:ATRA) CEO Isaac E. Ciechanover sold 1,000 shares of the firm’s stock in a transaction that occurred on Monday, March 12th. The stock was sold at an average price of $46.31, for a total value of $46,310.00. Following the completion of the sale, the chief executive officer now owns 812,613 shares of the company’s stock, valued at approximately $37,632,108.03. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Shares of NASDAQ ATRA traded down $1.30 during midday trading on Friday, hitting $35.15. The stock had a trading volume of 358,230 shares, compared to its average volume of 781,519. The stock has a market capitalization of $1,364.73, a P/E ratio of -8.79 and a beta of 2.55. Atara Biotherapeutics has a fifty-two week low of $11.80 and a fifty-two week high of $49.90.

How to Become a New Pot Stock Millionaire

Atara Biotherapeutics (NASDAQ:ATRA) last released its earnings results on Tuesday, February 27th. The biotechnology company reported ($1.15) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($1.15). equities research analysts forecast that Atara Biotherapeutics will post -3.62 earnings per share for the current year.

A number of analysts have commented on ATRA shares. Canaccord Genuity reiterated a “buy” rating on shares of Atara Biotherapeutics in a research report on Friday, December 29th. ValuEngine upgraded Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Friday, December 29th. Citigroup raised Atara Biotherapeutics from a “sell” rating to a “neutral” rating and set a $18.00 price target for the company in a report on Wednesday, January 3rd. BidaskClub raised Atara Biotherapeutics from a “hold” rating to a “buy” rating in a report on Thursday, January 11th. Finally, Cowen started coverage on Atara Biotherapeutics in a report on Friday, January 26th. They set an “outperform” rating for the company. One analyst has rated the stock with a sell rating, five have assigned a hold rating and five have given a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $33.80.

Institutional investors have recently made changes to their positions in the stock. SG Americas Securities LLC acquired a new stake in shares of Atara Biotherapeutics during the third quarter worth $142,000. Voya Investment Management LLC grew its stake in shares of Atara Biotherapeutics by 16.2% during the second quarter. Voya Investment Management LLC now owns 11,813 shares of the biotechnology company’s stock worth $165,000 after purchasing an additional 1,651 shares during the period. Russell Investments Group Ltd. bought a new position in Atara Biotherapeutics during the third quarter worth about $170,000. MetLife Investment Advisors LLC bought a new position in Atara Biotherapeutics during the fourth quarter worth about $217,000. Finally, The Manufacturers Life Insurance Company lifted its holdings in Atara Biotherapeutics by 7.2% during the second quarter. The Manufacturers Life Insurance Company now owns 20,377 shares of the biotechnology company’s stock worth $285,000 after acquiring an additional 1,369 shares in the last quarter. 76.88% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This report was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another website, it was illegally stolen and republished in violation of U.S. & international copyright law. The correct version of this report can be read at https://www.dispatchtribunal.com/2018/04/08/atara-biotherapeutics-inc-atra-ceo-sells-46310-00-in-stock.html.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company is developing tabelecleucel, an advanced T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.

Insider Buying and Selling by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply